Pulmonary lymphangioleiomyomatosis (LAM)
Journal
Македонски медицински преглед = Macedonian medical review
Date Issued
2023-04-08
Author(s)
Tochko, Aleksandra
Abstract
Lymphangioleiomyomatosis (LAM) is a multisystem disorder affecting kidneys and lymphatics, with primary pathology involving the lungs.
Pulmonary lymphangioleiomyomatosis is a rare lung disease characterized by diffuse cystic changes caused by a destructive proliferation of smooth muscle-like cells or LAM cells. It is a part of the perivascular epithelioid cell family of tumors. LAM may be associated with the genetic disorder tuberous sclerosis complex or may occur sporadically. Individuals affected by LAM are typically females of reproductive age who present with dyspnea, chest pain, coughing, hemoptysis or recurrent spontaneous pneumothorax. Definitive diagnosis of LAM is usually based on pathologic results and immunohistochemically staining lung biopsy specimens obtained through the chest wall or during endoscopic surgery for pneumothorax. Patients may receive immunosuppressant therapy to suppress respiratory decline and/or undergo pleurodesis to prevent complications such as pneumothorax. Traditionally, LAM was managed via lung transplantation exclusively, however, with genetic testing and an increase in the patient study population, alternative management techniques are being researched.
Pulmonary lymphangioleiomyomatosis is a rare lung disease characterized by diffuse cystic changes caused by a destructive proliferation of smooth muscle-like cells or LAM cells. It is a part of the perivascular epithelioid cell family of tumors. LAM may be associated with the genetic disorder tuberous sclerosis complex or may occur sporadically. Individuals affected by LAM are typically females of reproductive age who present with dyspnea, chest pain, coughing, hemoptysis or recurrent spontaneous pneumothorax. Definitive diagnosis of LAM is usually based on pathologic results and immunohistochemically staining lung biopsy specimens obtained through the chest wall or during endoscopic surgery for pneumothorax. Patients may receive immunosuppressant therapy to suppress respiratory decline and/or undergo pleurodesis to prevent complications such as pneumothorax. Traditionally, LAM was managed via lung transplantation exclusively, however, with genetic testing and an increase in the patient study population, alternative management techniques are being researched.
File(s)![Thumbnail Image]()
![Thumbnail Image]()
Loading...
Name
IMG-893f2b6f650afb93b8e078d9a620c7c5-V.jpg
Size
265.07 KB
Format
JPEG
Checksum
(MD5):89443478ad41ac541ea7081713289815
Loading...
Name
IMG-03c42543c8400624abe95905b64ad1fc-V.jpg
Size
179.57 KB
Format
JPEG
Checksum
(MD5):2566b71e16dff5a10f790c5fb9060f66
